Trial Profile

A Phase IIa trial of Ampligen (rintatolimod) in combination with checkpoint inhibitors for the treatment of advanced urothelial cancer, renal cell carcinoma and Melanoma (Second line therapy or greater, combination therapy)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Aug 2019 According to a Hemispherx Biopharma media release, Dr. David Strayer is the Principal Investigator
17 Oct 2018 New trial record
10 Oct 2018 According to Hemispherx Biopharma media release, this trial will be led by Pawel Kalinski, MD, PhD, Vice Chair for Translational Research and Professor of Oncology in the Department of Medicine and Co-Leader of the Tumor Immunology and Immunotherapy Program at Roswell Park, in collaboration with Mateusz Opyrchal, MD, PhD, of the Roswell Park Department of Medicine.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com